[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611829":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":39,"locations":45,"responsibleParty":75,"collaborators":30,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":30,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":30,"enrollmentInfo":87,"targetDuration":30,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":48,"whyStopped":30,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Propedix, Inc.","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Tolnaftate Stick Formula A","EXPERIMENTAL","Participants will receive Formula A, a topical 1% tolnaftate formulation delivered through a stick-based applicator. The product is applied twice daily for four weeks.",[13],"Drug: 1% Tolnaftate Stick Formula A",{"label":15,"type":10,"description":16,"interventionNames":17},"Tolnaftate Stick Formula B","Participants will receive Formula B, a topical 1% tolnaftate formulation delivered through a stick-based applicator. The product is applied twice daily for four weeks.",[18],"Drug: 1% Tolnaftate Stick Formula B",{"label":20,"type":10,"description":21,"interventionNames":22},"Tolnaftate Stick Formula C","Topical antifungal stick containing 1% tolnaftate in the Formula C base. Applied twice daily for 4 weeks.",[23],"Drug: 1% Tolnaftate Stick Formula C",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","1% Tolnaftate Stick Formula A","Topical antifungal stick containing 1% tolnaftate in the Formula A base. Applied twice daily for 4 weeks.",[9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"1% Tolnaftate Stick Formula B","Topical antifungal stick containing 1% tolnaftate in the Formula B base. Applied twice daily for 4 weeks.",[15],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"1% Tolnaftate Stick Formula C","Topical antifungal stick containing 1% tolnaftate in the PP2C-2003 base formulation. Applied twice daily for 30 days.",[20],[40],{"name":41,"role":42,"phone":43,"phoneExt":30,"email":44},"Prinicipal Investigator","CONTACT","617-869-0126","cschanbacher@propedix.com",[46,64],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Kuchnir Dermatology and Dermatological Surgery","RECRUITING","Framingham","Massachusetts","01701","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-71.41617,42.27926,{"lat":58,"lon":57},[61],{"name":41,"role":42,"phone":62,"phoneExt":30,"email":63},"508-872-2220","clinicalresearch@propedix.com",{"facility":47,"status":48,"city":65,"state":50,"zip":66,"country":52,"countryCode":53,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Milford","01757",{"type":55,"coordinates":68},[69,70],-71.51617,42.13982,{"lat":70,"lon":69},[73],{"name":41,"role":42,"phone":74,"phoneExt":30,"email":63},"508-478-2610",{"type":76,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100611829","phase-2-topical-tolnaftate-stick-for-tinea-pedis-an-open-label-interventional-study-100611829",false,"NCT07245667","Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study","Clinical Study to Assess Tolnaftate 1% With a Novel Vehicle for the Treatment of Tinea Pedis","Inclusion Criteria:\n\n* Male or female, aged 16 or above\n* Clinical diagnosis of tinea pedis (For Cohort 4, positive symptomology is acceptable)\n* Confirmation of diagnosis with positive potassium hydroxide (KOH) microscopy (For Cohort 4, a negative KOH test is acceptable)\n* Signed and dated informed consent form\n* Willingness to comply with study protocol and availability for the duration of the study\n\nExclusion Criteria:\n\n* Diagnosis of moccasin-type tinea pedis\n* Presence of serous exudate or pus\n* Treatment with a topical antifungal in the past 2 weeks\n* Treatment with a systemic antifungal in the past 4 weeks\n* Concurrent immunosuppressive or antimicrobial therapy\n* Liver disease\n* Pregnancy or breastfeeding\n* Use any other antifungal therapy during trial or within three months of starting the trial\n* Known hypersensitivity to any ingredients of trial agents\n* Patients with a current diagnosis of diabetes or neuropathy",true,"ALL","16 Years",{"count":88,"type":89},150,"ESTIMATED","INTERVENTIONAL",[92],"PHASE2","This study is designed to evaluate the safety and effectiveness of multiple 1% tolnaftate formulations delivered through novel stick-based vehicles in individuals with tinea pedis (athlete's foot).",[95],"Tinea Pedis",[97,98],"tinea pedis","athletes foot","2025-11-23",{"date":101,"type":102},"2025-11-28","ACTUAL",{"date":104,"type":102},"2024-12-30",{"date":106,"type":89},"2026-02",{"name":5,"class":6},2]